MBX Biosciences

Edit info

Founded: 2019

Location: Carmel, Indiana

Employee range: 1-50

Clinical stage: Clin2

Therapy area: Hypoparathyroidism

Drug types: END, HEM, NWL, RAR

Lead product: MBX 2109

Funding: 100 - 500M

www.mbxbio.com

linkedin.com

job board

Drug notes:

MBX 1416 Clin1 post-bariatric hypoglycemia; MBX 4291 Clin0 obesity; undisclosed programs RD rare diseases, undisclosed

About:

MBX Biosciences is a clinical-stage biopharmaceutical company pioneering the development of Precision Endocrine Peptides (PEP™) for endocrine and metabolic disorders. Their innovative approach focuses on engineering peptides to improve their drug-like properties, enabling more effective and convenient treatments. MBX Biosciences is developing treatments for conditions such as hypoparathyroidism and post-bariatric hypoglycemia. They are also exploring the potential of their PEP™ platform for treating metabolic disorders. Their lead product, MBX 2109, a long-acting parathyroid hormone (PTH) analog being developed for the treatment of chronic hypoparathyroidism. It is currently in Phase 2 clinical trials. MBX Biosciences' innovative approach offers several advantages.